Targeting chromatin remodeling to prevent cardiovascular disease in diabetes

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Epigenetics

Background:

• Diabetes is a growing global health crisis, significantly increasing cardiovascular morbidity and mortality.
• Intensive glycemic control has not consistently reduced cardiovascular events in diabetic patients, suggesting underlying mechanisms beyond current blood sugar management.
• The concept of 'metabolic memory' explains persistent cardiovascular damage in diabetes, even after achieving target HbA1c levels.

Purpose of the Study:

• To critically review evidence linking epigenetic modifications to diabetic cardiovascular complications.
• To explore the potential of chromatin-modifying agents in reversing adverse epigenetic changes and treating cardiometabolic diseases.

Main Methods:

• Review of recent scientific literature on diabetes, cardiovascular disease, metabolic memory, and epigenetics.
• Analysis of studies investigating DNA/histone complex modifications and their role in gene expression.
• Examination of emerging therapeutic compounds targeting epigenetic pathways.

Main Results:

• Hyperglycemic environments induce persistent epigenetic alterations in cardiovascular systems.
• These epigenetic changes modulate oxidant and inflammatory genes, leading to sustained cardiac and vascular dysfunction.
• Compounds like histone deacetylase and histone acetyltransferase inhibitors show promise in erasing detrimental chromatin signatures.

Conclusions:

• Chromatin alterations are identified as key drivers of cardiovascular disease in the context of diabetes.
• Epigenetic modifications represent a critical mechanism underlying 'metabolic memory' in diabetic vascular complications.
• Chromatin modifying agents offer a promising therapeutic strategy for reprogramming detrimental epigenetic signatures in patients with cardiometabolic disturbances.